These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders". Eardley I Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052 [No Abstract] [Full Text] [Related]
25. [Erectile dysfunction in patients with ischemic heart disease (review )]. Gamidov SI; Mazo EB; Ovchinnikov RI; Iremashvili VV Ter Arkh; 2004; 76(10):75-80. PubMed ID: 15575483 [No Abstract] [Full Text] [Related]
27. The use of drugs Impaza and Nebido in the treatment of erectile dysfunction in patients with type 2 diabetes mellitus of reproductive age. Mehtiyev T Georgian Med News; 2013 Jun; (219):61-5. PubMed ID: 23863213 [TBL] [Abstract][Full Text] [Related]
28. Viagra and male erectile dysfunction: prescribing restrictions should be abolished. Jackson G Int J Clin Pract; 2000 May; 54(4):207. PubMed ID: 10912305 [No Abstract] [Full Text] [Related]
29. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. Schiff JD; Bar-Chama N; Cesaretti J; Stock R BJU Int; 2006 Dec; 98(6):1255-8. PubMed ID: 17125483 [TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. Axilrod AC Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309 [TBL] [Abstract][Full Text] [Related]
32. [Vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy]. Huang YR Zhonghua Nan Ke Xue; 2005 Jan; 11(1):76-9. PubMed ID: 15704689 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway. Giuliano F Eur Urol; 2009 Jan; 55(1):49-51. PubMed ID: 18938025 [No Abstract] [Full Text] [Related]
35. [Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction]. He ZJ; Zhang K; Jin J; Li NC; Na YQ; Bai WJ; Wang XF; Zhu JC; Jiang H; Yuan RP; Hong BF; Song T; Yang Y; Dai DX Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1080-3. PubMed ID: 17201251 [TBL] [Abstract][Full Text] [Related]
36. [Erectile dysfunction: treatment with type 5 phosphodiesterase inhibitors]. Sociedade Brasileira de Urologia Rev Assoc Med Bras (1992); 2007; 53(2):102-3. PubMed ID: 17568908 [No Abstract] [Full Text] [Related]
37. Impact of sildenafil on male erectile disorder due to psychological factors. Fishbain DA Can J Psychiatry; 2000 Feb; 45(1):85-6. PubMed ID: 10696497 [No Abstract] [Full Text] [Related]
38. Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. Brock GB; Bochinski D Curr Opin Urol; 2001 Nov; 11(6):625-30. PubMed ID: 11734700 [TBL] [Abstract][Full Text] [Related]
39. The role of statins in erectile dysfunction. Ferrer E; Moral MA; Bozzo J Drugs Today (Barc); 2007 Jan; 43(1):55-9. PubMed ID: 17315053 [TBL] [Abstract][Full Text] [Related]
40. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]